How is Sinus Rhythm Maintained in Paroxysmal Atrial Fibrillation? 1

Abstract

Get full access to this article

View all access options for this article.

References

Waktare

JEP

Camm

. Atrial fibrillation. In: Jackson

, ed. Difficult Cardiology III. London: Martin Dunitz; 1997.

Gallagher

Camm

. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997; 20:1603–5.

Rodriguez

Smeets

Xie

. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993; 72:1137–41.

Wolf

Dawber

Thomas

Kannel

. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28:973–7.

Page

Wilkinson

Clair

. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89:224–7.

Rawles

Metcalfe

Jennings

. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990; 63:225–7.

Leitch

Klein

Yee

. Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response? Circulation 1992; 85:1064–71.

Wijffels

MCEF

Kirchhof

CJHJ

Dorland

Allessie

. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995; 92:1954–68.

Sanfilippo

Abascal

Sheehan

. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990; 82:792–7.

10.

Vaziri

Larson

Benjamin

Levy

. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994; 89:724–30.

11.

Sulke

Kamalvand

Tan

. A prospective evaluation of recurrent atrial endocardial defibrillation in patients with refractory chronic atrial fibrillation and flutter. Heart 1996; 75:P42.

12.

Anderson

Gilbert

Alpert

. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989; 80:1557–70.

13.

Van Wijk

den Heijer

Crijns

. Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 1989; 13:32–6.

14.

Aliot

Denjoy

. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 1996; 77:66A-71A.

15.

Cobbe

. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachyarrythmias. J Am Coll Cardiol 1994; 23:251A.

16.

Connolly

Hoffert

. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989; 63:817–9.

17.

Lee

Chen

Chiang

. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. Journal of Internal Medicine 1996; 239:253–60.

18.

Lee

Chen

Tai

. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997; 79:905–8.

19.

Reimold

Cantillon

Friedman

Antman

. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71:558–63.

20.

Blevins

Kerin

Benaderet

. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987; 147:1401–4.

21.

Martin

Benbow

Leach

Bailey

. Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter. Br J Clin Pract Symp Suppl 1986; 44:52–60.

22.

Murgatroyd

O'Farrell

Foran

. A multi-centre double blind crossover comparison of disopyramide, atenolol, and placebo for symptomatic paroxysmal atrial fibrillation. J Am Coll Cardiol 1995:231A.

23.

Murgatroyd

Curzen

Aldergather

. Clinical features and drug therapy in patients with paroxysmal atrial fibrillation: results of the CRAFT multi-center database. J Am Coll Cardiol 1993; 21:380A.

24.

Naccarelli

Dorian

Hohnloser

Coumel

. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996; 77:53A-59A.

25.

Pritchett

ELC

McCarthy

Wilkinson

. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Int Med 1991; 114:539–44.

26.

Pietersen

Hellemann

. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 1991; 67:713–7.

27.

Investigators TCASTC. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406–12.

28.

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992; 327:227–33.

29.

Waldo

Camm

deRuyter

. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7–12.

30.

Cairns

Connolly

Roberts

Gent

. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675–82.

31.

Julian

Camm

Frangin

. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667–74.

32.

Coplen

Antman

Berlin

. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82:1106–16.

33.

Pritchett

ELC

Wilkinson

. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991; 67:976–80.

34.

Coumel

Leclercq

Assayag

. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 1984; 54:60D-66D.

35.

Cox

Boineau

Schuessler

. Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. J Thorac Cardiovasc Surg 1995; 110:473–84.

36.

Cox

Jaquiss

Schuessler

Boineau

. Modification of the Maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the Maze III procedure. J Thorac Cardiovasc Surg 1995; 110:485–95.

37.

Izumoto

Kawazoe

Kitahara

. Can the Maze procedure be combined safely with mitral valve repair? Journal of Heart Valve Disease 1997; 6:166–70.

38.

Kobayashi

Kosakai

Isobe

. Rationale of the Cox Maze procedure for atrial fibrillation during redo mitral valve operations. Journal of Thoracic & Cardiovascular Surgery 1996; 112:1216–21; discussion1222.

39.

Kosakai

Kawaguchi

Isobe

. Modified Maze procedure for patients with atrial fibrillation undergoing simultaneous open heart surgery. Circulation 1995; 92:II359–64.

40.

Marshall

Harris

Griffith

Gammage

. Randomised Prospective trial of Ablation and Pacing Versus Medical Therapy for Paroxysmal Atrial Fibrillation. Pacing Clin Electrophysiol 1998; 21:983.

41.

Levy

Lacombe

Cointe

Bru

. High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol 1988; 12:514–8.

42.

Schmitt

Alt

Plewan

. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 1996; 28:994–9.